The stock price of Prothena Corporation plc (NASDAQ: PRTA) has plunged by -6.92 when compared to previous closing price of 14.88, but the company has seen a -9.65% decline in its stock price over the last five trading sessions. businesswire.com reported 2024-12-30 that DUBLIN–(BUSINESS WIRE)—- $PRTA #prothena–Prothena announced that Oleg Nodelman will step down from Prothena’s Board of Directors to create time to focus on existing and new endeavors.
Is It Worth Investing in Prothena Corporation plc (NASDAQ: PRTA) Right Now?
Company’s 36-month beta value is 0.08.Analysts have differing opinions on the stock, with 5 analysts rating it as a “buy,” 3 as “overweight,” 2 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for PRTA is 44.79M, and currently, short sellers hold a 19.64% ratio of that floaft. The average trading volume of PRTA on January 01, 2025 was 577.09K shares.
PRTA’s Market Performance
PRTA’s stock has seen a -9.65% decrease for the week, with a -14.56% drop in the past month and a -16.82% fall in the past quarter. The volatility ratio for the week is 8.01%, and the volatility levels for the past 30 days are at 10.22% for Prothena Corporation plc The simple moving average for the last 20 days is -3.19% for PRTA stock, with a simple moving average of -30.33% for the last 200 days.
Analysts’ Opinion of PRTA
Many brokerage firms have already submitted their reports for PRTA stocks, with Chardan Capital Markets repeating the rating for PRTA by listing it as a “Buy.” The predicted price for PRTA in the upcoming period, according to Chardan Capital Markets is $40 based on the research report published on December 20, 2024 of the previous year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see PRTA reach a price target of $38, previously predicting the price at $68. The rating they have provided for PRTA stocks is “Neutral” according to the report published on January 30th, 2024.
Deutsche Bank gave a rating of “Buy” to PRTA, setting the target price at $62 in the report published on December 12th of the previous year.
PRTA Trading at -10.45% from the 50-Day Moving Average
After a stumble in the market that brought PRTA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -66.66% of loss for the given period.
Volatility was left at 10.22%, however, over the last 30 days, the volatility rate increased by 8.01%, as shares sank -7.67% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -19.05% lower at present.
During the last 5 trading sessions, PRTA fell by -9.65%, which changed the moving average for the period of 200-days by -46.87% in comparison to the 20-day moving average, which settled at $14.31. In addition, Prothena Corporation plc saw -61.89% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at PRTA starting from Walker Karin L, who sale 5,000 shares at the price of $34.00 back on Jan 24 ’24. After this action, Walker Karin L now owns 0 shares of Prothena Corporation plc, valued at $170,000 using the latest closing price.
Stock Fundamentals for PRTA
Current profitability levels for the company are sitting at:
- -1.26 for the present operating margin
- 0.45 for the gross margin
The net margin for Prothena Corporation plc stands at -0.99. The total capital return value is set at -0.31. Equity return is now at value -22.90, with -19.64 for asset returns.
Currently, EBITDA for the company is -190.11 million with net debt to EBITDA at 3.19. When we switch over and look at the enterprise to sales, we see a ratio of 1.78. The liquidity ratio also appears to be rather interesting for investors as it stands at 11.52.
Conclusion
In a nutshell, Prothena Corporation plc (PRTA) has experienced a bad performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
